CMV INFECTIONS IN AIDS PATIENTS ON ANTI-VIRAL CLINICAL PROTOCOLS

(1)项目目标： 由于巨细胞病毒是公认的主要机会性感染之一， 对于艾滋病患者，监测血液、尿液和组织是很重要的 来自参加各种临床试验的患者的样本， CMV的存在。 (2)临床方案受试者： (a)针对HIV-1的联合疗法：AZT/IL 2、IFN-α/IL 2和 AZT、IFN和AZT/IFN组合的三组试验。 (b)确定CMV-IG疗效的随机双盲试验 预防艾滋病患者的巨细胞病毒感染。 (c)使用胞嘧啶衍生物（HPMPC）预防糖尿病的I期试验 和/或治疗AIDS患者中的CMV感染。 (d)腺嘌呤类似物（PMEA）作为潜在药物的I期试验， 对HIV-1和疱疹病毒具有双重抗病毒作用。（患者 艾滋病患者CD 4 <200）。 (e)这个项目的另一个目标是确定巨细胞病毒是否可以被隔离 从无症状以及 有症状的HIV-1患者。它可能提供了一个早期指标， 在这些患者中重新激活CMV，并导致早期开始抗- CMV治疗预防全身暴发性疾病。 (3)主要发现： 大多数审判正在进行中。试验（a）的初步结果表明， CMV-IG不能减少治疗患者的CMV病毒尿， 作为预防剂有益。

(1) Goals of Project: Since CMV is recognized as one of the leading opportunistic infections in AIDS patients, it is important to monitor blood, urine, and tissue specimens from patients enrolled in various clinical trials for the presence of CMV. (2) Subjects of Clinical Protocols: (a) Combination therapies against HIV-1 : AZT/IL2, IFN-alpha /IL2, and a three arm trial of combination AZT, IFN, and AZT/IFN. (b) A randomized double blind trial to determine the efficacy of CMV-IG as prophylaxis for CMV infections in AIDS patients. (c) Phase I trial with a Cytosine derivative (HPMPC) for the preventio and/or treatment of CMV infections in AIDS patients. (d) Phase I trial of an Adenine analog (PMEA) as a potential drug with dual anti-viral effects on HIV-1 and Herpes viruses. (patient population: AIDS with CD4 <200). (e) Another goal of this project is to determine if CMV can be isolated from bronchial lavage specimens taken from asymptomatic as well as symptomatic HIV-1 patients. It may provide an early indicator of reactivated CMV in these patients, and lead to early initiation of anti- CMV treatment to prevent systemic fulminating disease. (3) Major Findings: Most Trials are ongoing. Preliminary results from trial (a) suggest tha CMV-IG did not decrease CMV viruria in treated patients and may not be beneficial as a prophylactic agent.